JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on healthcare and fintech, announced today that its wholly-owned subsidiary, ALT5 Sigma, has launched a new service named "ALT5 Settlement Platform" aimed at the untapped Global Digital Content Creation Market.
Save time and jump to the most important pieces.
Record quarter for ALT5 with Q3 revenue of $4.94 millionNew customer onboarding strong in Q3 and continuing into Q4Launching additional capabilities for Alt5 Prime and Alt5 Pay in Q4 2024 and Q1 2025LAS VEGAS, NV / ACCESSWIRE / November 12, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, announced financial results for its third fiscal quarter ended September 28, 2024."ALT5 Sigma's fintech segment delivers record performance in Q3, marking the first full quarter since the completion of the acquisition. We are
LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, is pleased to announce the appointment of Mr. Ron Pitters to its Board of Directors."We are thrilled to welcome industry veteran, Ron Pitters, to our Board. With a unique blend of experience in both traditional finance and disruptive blockchain technologies, Ron brings invaluable insights. His proven track record, spanning from startups to multinational corporations, makes him a fantastic addition to our team,"
Premier Event to Showcase Growth Companies and Foster High-Level Investor EngagementLAS VEGAS, NV / ACCESSWIRE / October 30, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), is proud to announce its participation in Spartan Capital Securities, LLC's inaugural investor conference on November 4th at the prestigious Pierre Hotel in New York.This participation aligns with our commitment to engage with industry leaders and investors. Our presentation will offer insight into our company's growth strategy and market position.Presenting Company Brief Description.Vay Tham, ALT5's CRO commented, "We are pleased to be invited and to present at Spartan Capital's inaugural investor conference. This event pro
LAS VEGAS, NV / ACCESSWIRE / November 6, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS) ("ALT5" or the "Company"), a fintech innovator providing next-generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and secure storage of digital assets, is pleased to announce the appointment of Mr. Ron Pitters to its Board of Directors."We are thrilled to welcome industry veteran, Ron Pitters, to our Board. With a unique blend of experience in both traditional finance and disruptive blockchain technologies, Ron brings invaluable insights. His proven track record, spanning from startups to multinational corporations, makes him a fantastic addition to our team,"
LAS VEGAS, June 26, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on healthcare and fintech, is pleased to announce that it has appointed Mr. Vay Tham as its Chief Revenue Officer and President of ALT5 Sigma, Inc., its wholly-owned subsidiary. Mr. Tham brings extensive experience in capital markets, particularly in technology sectors, spanning over 25 years. His career includes roles in research, investment banking, and finance, notably and most recently as Managing Director and Head of Technology Investment Banking at PI Financial Corp. (Ventum Financial).
LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D. to its Scientific Advisory Board (SAB). Dr. Goeders is considered one of the world's leaders on the role of stress in drug addiction. Tony Isaac, President and Chief Executive Officer of JanOne, commented, "JanOne's mission is to develop non-addictive medications to treat diseases that cause severe pain, thereby m
JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on fintech and healthcare, confirmed today that, as of market open on Monday, July 15, 2024, the Company's new name will be "ALT5 Sigma Corporation" and its Nasdaq common stock ticker symbol will change to "ALTS". This will replace the Company's current ticker symbol "JAN". Further, the Company's website address will change from "janone.com" to "alt5sigma.com."
Gainers Ainos (NASDAQ:AIMD) stock rose 54.8% to $1.27 during Friday's pre-market session. The market value of their outstanding shares is at $8.2 million. Longeveron (NASDAQ:LGVN) shares moved upwards by 34.15% to $3.61. The company's market cap stands at $22.9 million. Bio-Path Hldgs (NASDAQ:BPTH) shares increased by 20.99% to $2.42. The market value of their outstanding shares is at $4.4 million. Moleculin Biotech (NASDAQ:MBRX) stock moved upwards by 17.24% to $5.1. The market value of their outstanding shares is at $11.7 million. Tonix Pharmaceuticals (NASDAQ:TNXP) shares moved upwards by 12.84% to $1.23. The company's market cap stands at $3.6 million. Molecular Partners (NASDAQ:MO
SC 13G/A - JanOne Inc. (0000862861) (Subject)
SC 13G - JanOne Inc. (0000862861) (Subject)
SC 13G/A - JanOne Inc. (0000862861) (Subject)
4 - JanOne Inc. (0000862861) (Issuer)
4 - JanOne Inc. (0000862861) (Issuer)
4 - JanOne Inc. (0000862861) (Issuer)
8-K - ALT5 Sigma Corp (0000862861) (Filer)
8-K - JanOne Inc. (0000862861) (Filer)
424B5 - JanOne Inc. (0000862861) (Filer)
-The board has approved a strategic review of the biotech assets and ALT5 Sigma being the core focus going forward- -The company is intending a name and stock symbol change to reflect this decision- LAS VEGAS, July 10, 2024 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a multidisciplinary organization with a focus on fintech and healthcare, has announced plans to enhance stockholder value through a visionary strategic realignment, entailing a redeployment of biotech assets and a change of its name. The plan, unanimously approved by the company's board and following the May acquisi
The acquisition of Soin provides JanOne with its second, late stage clinical stage asset LAS VEGAS, Jan. 10, 2023 /PRNewswire/ -- JanOne Inc. ("JanOne") (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that it has completed the acquisition of Soin Therapeutics, LLC and its product, a patent-pending, novel formulation of low-dose naltrexone. This all stock transaction has a value of $13M, with up to an additional $17M depending on revenues generated by the product, for a total value of up to $30M. The transaction includes restrictions on the maximum number of shares of preferred stock and common stock that can be i
LAS VEGAS, Dec. 7, 2021 /PRNewswire/ -- JanOne Inc. (NASDAQ:JAN), a company that focuses on the development of drugs with non-addictive, pain-relieving properties - in an effort to further reduce the drug addiction epidemic - today announced an option agreement for the rights to a novel strategy to reduce methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO). The agreement with LSU Health Shreveport, along with other intellectual property relating to TSPO's role in treating meth use disorder (MUD), provides JanOne Inc. with an opportunity to identify new drugs to enhance TSPO activity, and by doing so, reducing craving for meth. This new strategy for treating MUD w